FDA Narrows Leucovorin Autism Claims to Ultra‑Rare Brain Disorder

NPR reports that after a high‑profile Trump administration press conference last fall touting leucovorin (folinic acid) as a potential treatment for autism, federal health officials have now quietly walked back that claim and limited formal approval to a tiny subset of patients with FOLR1‑related cerebral folate transport deficiency. In a briefing last week, a senior FDA official said there is not yet sufficient data to establish leucovorin’s efficacy for autism more broadly and stressed that its established use is for cerebral folate deficiency, an ultra‑rare condition with fewer than 50 documented cases worldwide. The initial federal messaging triggered a surge of demand among U.S. parents of autistic children, spawning social media groups with tens of thousands of members trading referrals and putting heavy pressure on clinicians. Autism specialists like UCLA’s Dr. Shafali Jeste describe the new wave of leucovorin requests as a major distraction, noting that the study used to suggest widespread cerebral folate deficiency in autism was small and not strong enough to justify routine prescribing. The episode underscores how expansive government claims about treatments can rapidly outpace the science, forcing doctors to undo expectations and leaving families caught between hope, online hype and more cautious medical guidance.